Inhibition of ERAP1 represses HLA-B27 free heavy chains expression on polarized macrophages and interrupts NK cells activation and function from ankylosing spondylitis

Inhibition of ERAP1 represses HLA-B27 free heavy chains expression on polarized macrophages and interrupts NK cells activation and function from ankylosing spondylitis

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 248(2023) vom: 20. März, Seite 109268
1. Verfasser: Babaie, Farhad (VerfasserIn)
Weitere Verfasser: Mohammadi, Hamed, Salimi, Sorayya, Ghanavatinegad, Alireza, Abbasifard, Mitra, Yousefi, Mehdi, Hajaliloo, Mehrzad, Khalili, Younes, Zamanlou, Sajjad, Safari, Roghaiyeh, Hemmatzadeh, Maryam, Rezaiemanesh, Alireza, Salimi, Reza, Baradaran, Behzad, Babaloo, Zohreh
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Ankylosing spondylitis Endoplasmic reticulum aminopeptidase 1 Free heavy chains Human leukocyte antigen-B27 Macrophage Natural killer cell HLA-B27 Antigen Minor Histocompatibility Antigens mehr... ERAP1 protein, human EC 3.4.11.- Aminopeptidases
LEADER 01000naa a22002652 4500
001 NLM353108766
003 DE-627
005 20231226055241.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109268  |2 doi 
028 5 2 |a pubmed24n1176.xml 
035 |a (DE-627)NLM353108766 
035 |a (NLM)36804470 
035 |a (PII)S1521-6616(23)00047-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Babaie, Farhad  |e verfasserin  |4 aut 
245 1 0 |a Inhibition of ERAP1 represses HLA-B27 free heavy chains expression on polarized macrophages and interrupts NK cells activation and function from ankylosing spondylitis 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 14.03.2023 
500 |a Date Revised 18.03.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: We aimed to assess if Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms might impress Human leukocyte antigen (HLA)-B27-free heavy chains (FHCs) expression on macrophages and eventually NK cell activation in Ankylosing spondylitis (AS) 
520 |a METHODS: Blood samples were obtained from 10 HLAB27+ patients with protective and 10 HLAB27+ patients with non-protective genotype. Monocytes were isolated and polarized toward M1 and M2 macrophages. ERAP1 was inhibited in macrophages, which were then co-cultured with autologous NK cells 
520 |a RESULTS: Expression of HLA-B27-FHCs on M1 and M2 macrophages was reduced in patients with protective ERAP1 genotype. Co-culturing ERAP1-inhibited M1 macrophages and NK cells from patients with protective genotype resulted in downmodulation of CD69 and CD107a markers on NK cells and reduced number of IFN-γ+ NK cells compared to that of patients with non-protective genotypes 
520 |a CONCLUSION: Inhibition of ERAP1 activity, by diminishing NK activation, may have therapeutic value in treating AS patients 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Ankylosing spondylitis 
650 4 |a Endoplasmic reticulum aminopeptidase 1 
650 4 |a Free heavy chains 
650 4 |a Human leukocyte antigen-B27 
650 4 |a Macrophage 
650 4 |a Natural killer cell 
650 7 |a HLA-B27 Antigen  |2 NLM 
650 7 |a Minor Histocompatibility Antigens  |2 NLM 
650 7 |a ERAP1 protein, human  |2 NLM 
650 7 |a EC 3.4.11.-  |2 NLM 
650 7 |a Aminopeptidases  |2 NLM 
650 7 |a EC 3.4.11.-  |2 NLM 
700 1 |a Mohammadi, Hamed  |e verfasserin  |4 aut 
700 1 |a Salimi, Sorayya  |e verfasserin  |4 aut 
700 1 |a Ghanavatinegad, Alireza  |e verfasserin  |4 aut 
700 1 |a Abbasifard, Mitra  |e verfasserin  |4 aut 
700 1 |a Yousefi, Mehdi  |e verfasserin  |4 aut 
700 1 |a Hajaliloo, Mehrzad  |e verfasserin  |4 aut 
700 1 |a Khalili, Younes  |e verfasserin  |4 aut 
700 1 |a Zamanlou, Sajjad  |e verfasserin  |4 aut 
700 1 |a Safari, Roghaiyeh  |e verfasserin  |4 aut 
700 1 |a Hemmatzadeh, Maryam  |e verfasserin  |4 aut 
700 1 |a Rezaiemanesh, Alireza  |e verfasserin  |4 aut 
700 1 |a Salimi, Reza  |e verfasserin  |4 aut 
700 1 |a Baradaran, Behzad  |e verfasserin  |4 aut 
700 1 |a Babaloo, Zohreh  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 248(2023) vom: 20. März, Seite 109268  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:248  |g year:2023  |g day:20  |g month:03  |g pages:109268 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109268  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 248  |j 2023  |b 20  |c 03  |h 109268